Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Risk & Volatility
Celldex Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
Earnings & Valuation
This table compares Celldex Therapeutics and Shattuck Labs”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Celldex Therapeutics | $1.54 million | 1,491.56 | -$258.76 million | ($4.35) | -6.72 |
| Shattuck Labs | $1.00 million | 550.98 | -$48.81 million | ($0.51) | -10.76 |
Shattuck Labs has lower revenue, but higher earnings than Celldex Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Celldex Therapeutics and Shattuck Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Celldex Therapeutics | N/A | -52.35% | -47.61% |
| Shattuck Labs | N/A | -43.57% | -40.90% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Celldex Therapeutics and Shattuck Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Celldex Therapeutics | 1 | 1 | 11 | 0 | 2.77 |
| Shattuck Labs | 1 | 0 | 9 | 3 | 3.08 |
Celldex Therapeutics presently has a consensus price target of $63.08, suggesting a potential upside of 115.67%. Shattuck Labs has a consensus price target of $13.70, suggesting a potential upside of 149.54%. Given Shattuck Labs’ stronger consensus rating and higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Celldex Therapeutics.
Insider and Institutional Ownership
58.7% of Shattuck Labs shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Shattuck Labs beats Celldex Therapeutics on 10 of the 14 factors compared between the two stocks.
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
